PMID- 26245686
OWN - NLM
STAT- MEDLINE
DCOM- 20160819
LR  - 20230722
IS  - 1868-8500 (Electronic)
IS  - 1868-8497 (Print)
IS  - 1868-8497 (Linking)
VI  - 6
IP  - 5-6
DP  - 2015 Dec
TI  - Symptomatic Control of Neuroendocrine Tumours with Everolimus.
PG  - 254-9
LID - 10.1007/s12672-015-0233-2 [doi]
AB  - Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, increases 
      progression-free survival in patients with advanced neuroendocrine tumours. 
      Patients with neuroendocrine tumours and symptomatic carcinoid have inferior 
      health-related quality of life than those without symptoms. We aimed to evaluate 
      the effect of everolimus on symptomatic control of neuroendocrine tumours. 
      Fifteen patients with metastatic neuroendocrine disease pre-treated with depot 
      octreotide received combination everolimus and octreotide (midgut = 8, pancreatic 
      = 3, other = 4). Reasons for initiation of everolimus were progressive disease 
      (PD) by response evaluation criteria in solid tumours (n = 5), worsening 
      syndromic symptomology (n = 5), or both (n = 5). Symptomatic and objective 
      response and toxicity were evaluated using standard criteria. 7/10 patients who 
      were syndromic had improvements in symptomology, with a mean duration of symptom 
      control 13.9 months (range 1-39). All 10 symptomatic patients had non pancreatic 
      neuroendocrine (pNET) primaries, and with everolimus, 6/10 had reduced stool 
      frequency, 3/7 had a reduction of asthenia, and 5/7 had reduced frequency and 
      severity of flushing. Sixty percent of patients experienced any grade toxicities, 
      including the following: 40% grade 1/2 stomatitis, 7% grade 3/4 stomatitis, 20% 
      grade 1/2 rash, 13% diarrhoea, and one case of pneumonitis. In this cohort of 15 
      patients, we demonstrated that 70% of non pNET individuals with common carcinoid 
      syndrome symptoms resistant to depot octreotide had improvement in these symptoms 
      on institution of everolimus, with meaningful durations of symptom control. 
      Although this data is observational, to our knowledge, this represents the 
      largest analysis of carcinoid syndrome control with combined everolimus and 
      octreotide.
FAU - Bainbridge, Hannah E
AU  - Bainbridge HE
AD  - Department of Oncology, St Thomas' Hospital, Westminster Bridge Road, London, SE1 
      7EH, UK. hannahbainbridge@doctors.org.uk.
FAU - Larbi, Emmanuel
AU  - Larbi E
AD  - Department of Oncology, St Lukes Cancer Centre, Royal Surrey County Hospital, 
      Egerton Road, Guildford, GU2 7XX, UK.
FAU - Middleton, Gary
AU  - Middleton G
AD  - School of Cancer Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
LA  - eng
PT  - Journal Article
DEP - 20150806
PL  - United States
TA  - Horm Cancer
JT  - Hormones & cancer
JID - 101518427
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Combined Modality Therapy
MH  - Everolimus/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neuroendocrine Tumors/diagnosis/*drug therapy
MH  - Pancreatic Neoplasms/diagnosis/drug therapy
MH  - Retreatment
MH  - Retrospective Studies
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
PMC - PMC10355971
COIS- The authors declare that they have no competing interests.
EDAT- 2015/08/08 06:00
MHDA- 2016/08/20 06:00
PMCR- 2015/08/06
CRDT- 2015/08/07 06:00
PHST- 2015/02/27 00:00 [received]
PHST- 2015/07/20 00:00 [accepted]
PHST- 2015/08/07 06:00 [entrez]
PHST- 2015/08/08 06:00 [pubmed]
PHST- 2016/08/20 06:00 [medline]
PHST- 2015/08/06 00:00 [pmc-release]
AID - 10.1007/s12672-015-0233-2 [pii]
AID - 233 [pii]
AID - 10.1007/s12672-015-0233-2 [doi]
PST - ppublish
SO  - Horm Cancer. 2015 Dec;6(5-6):254-9. doi: 10.1007/s12672-015-0233-2. Epub 2015 Aug 
      6.